Compare KRYS & AXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRYS | AXS |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Bermuda |
| Employees | 295 | 1966 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 7.3B |
| IPO Year | 2017 | N/A |
| Metric | KRYS | AXS |
|---|---|---|
| Price | $340.21 | $105.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $297.60 | $121.29 |
| AVG Volume (30 Days) | 294.7K | ★ 615.3K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $389,130,000.00 | N/A |
| Revenue This Year | $38.74 | $2.53 |
| Revenue Next Year | $32.53 | $6.95 |
| P/E Ratio | $187.67 | ★ $8.43 |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $130.50 | $88.07 |
| 52 Week High | $356.50 | $110.34 |
| Indicator | KRYS | AXS |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 64.73 |
| Support Level | $253.89 | $99.46 |
| Resistance Level | N/A | $108.59 |
| Average True Range (ATR) | 12.77 | 2.56 |
| MACD | 2.68 | 0.80 |
| Stochastic Oscillator | 72.67 | 94.00 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States (U.S.), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of Insurance and Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States, and also has its presence in Ireland, Lloyd's of London, and Bermuda.